NASDAQ NMS - GLOBAL MARKET · IFRX
0.00% · $0.0000 · Vol 1.1M
After hours · updated 16:34:00 ET
InflaRx NV

InflaRx NV

Biotechnology
$1.56
Card
Relationship Map

Follow $IFRX

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $IFRX by email

Veridion Score

BETAMEDIUM CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
IFRX
InflaRx NV
Thu Oct 8 · session closed · Markets closed · resumes Fri 9:30 ET
Lower range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

40/ 100
Veridion Score
Lower range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Thu Oct 8 · session closed · Markets closed · resumes Fri 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is IFRX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading IFRX catalysts
About InflaRx NV
Biotechnology
Listed since
2017
Employees
65
Country
DE

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.55
Day high
$1.60
Day low
$1.47
Previous close
$1.56
52W high
$2.74
-43.07% from high
52W low
$0.8254
38% of range
Market cap
$229.9M
EPS
$-0.3489
Beta
1.31
Shares out
147.4M
Volume
1.1M
2.04× rel vol
Avg volume
559.7K
VWAP
$1.51
Price history computed in-house
1W
-8.77%
1M
-28.11%
3M
-23.90%
1Y
+6.12%
YTD
+54.46%
SMA 50 $1.98 · below
SMA 200 $1.60 · below
52W position 38%

IFRX overview

Veridion Score
40
Registered · 2026-10-08
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around IFRX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading IFRX Form 4 filings
Public disclosures

Congress activity in IFRX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

IFRX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for IFRX in this window.
Lobbying spend

IFRX lobbying filings, year to date.

Registered lobbying filings matched to InflaRx NV.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for IFRX in this window.
Loading news for IFRX
Analyst ratings
Sovereign unlock shows live analyst consensus for IFRX.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.